Apollomics

Apollomics is a biopharmaceutical company with a clear mission to discover and develop mono- and combination cancer therapies. Established in 2016, Apollomics has made strategic moves to operate in both the U.S. and China, aiming to harness synergies by collaborating with biotechnology companies in both the East and the West. Under the guidance of a seasoned management team, Apollomics has constructed a robust pipeline consisting of 10 drug candidates across 12 programs, 5 of which are undergoing clinical trials. These candidates are grouped based on their mechanisms of action, falling into three categories: "tumor inhibitors," "anti-cancer enhancers," and "immuno-oncology drugs." This diverse approach enables the development of synergistic combination therapies targeted at addressing unmet needs in cancer treatment. Moreover, the company has secured a $23.65M Post-IPO Equity investment on 30 March 2023. With a focus on biotechnology, healthcare, and pharmaceuticals industries, Apollomics is poised to make significant strides in the field of oncology. To stay updated on Apollomics’ latest advancements, visit their website at www.apollomicsinc.com.